



## **Diagnostics Biochem Canada Inc. (DBC) and Demeditec Diagnostics GmbH (Demeditec) agreed on a strategic partnership focused on ELISA distribution**

**London, Ontario, Canada and Kiel, Germany / October 23, 2024:** Today the Canadian company Diagnostics Biochem Canada, Inc. (DBC) and the German company Demeditec agreed on a strategic partnership focused on the distribution of DBC's unique portfolio of ELISA products. The goal of this cooperation is to combine the strengths of both companies for the expanded supply of high-quality ELISAs to many territorial regions worldwide, further expanding DBC's global reach through Demeditec's well established distribution network. DBC's portfolio includes a comprehensive menu of Endocrinology based analytes (e.g. steroids, hormones, and metabolic markers) as well as more specialized niche diagnostic markers such as Vasoactive Intestinal Polypeptide (VIP), Plasma Renin Activity and Total Estrogen. The expanded collaboration strengthens both companies with respect to the ongoing challenges of the new IVDR regulations.

### **Manon Hogue, CEO of DBC, comments:**

*"It has been our mission over the past 50 years to develop and market unique immunoassay kits that make a difference in the field of diagnostics and in public health. For this purpose, we are delighted to work with Demeditec, a company with extensive experience in distributing laboratory research and clinical products worldwide. Demeditec has a very strong position as they have an extensive network of partners in many countries around the world to further enhance DBC's global market penetration."*

### **Dr. Arndt Stüber, General Manager of Demeditec, comments:**

*"The distribution of ELISAs is a very important part of our core business and thus the partnership between Demeditec and DBC is an excellent step to strengthen this aspect of our company. We are convinced that our global customer base will benefit from the newly expanded menu of analytical tools, for both research and routine clinical diagnostic applications. Moreover, both companies feel well prepared to manage the challenges ahead due to the ever-changing regulatory landscape."*

### **For further information please contact:**

*Diagnostics Biochem Canada Inc.*

**[dbc-labs.com](http://dbc-labs.com)**

*Manon Hogue, CEO*

*Email: [mhogue@dbc-labs.com](mailto:mhogue@dbc-labs.com)*

*Phone: +1-519-681-8731*

*Demeditec Diagnostics GmbH*

**[demeditec.com](http://demeditec.com)**

*Dr. Arndt Stüber, General Manager*

*Email: [stueber@demeditec.de](mailto:stueber@demeditec.de)*

*Phone: +49-0431-719220*

### **About Diagnostics Biochem Canada Inc. (DBC)**

The mission of Diagnostics Biochem Canada Inc. (DBC) for over 50 years is to develop and market unique immunoassay kits that make a difference in the field of diagnostics and in public health.

As a manufacturer of high-quality immunoassays to a global market, DBC is constantly looking for new technologies and applications that can lead to an improvement in the diagnosis of disease and ultimately impact the quality of life for people around the world.

### **About Demeditec Diagnostics GmbH**

Since the foundation in 1987 Demeditec has rapidly grown to become a successful and reliable manufacturer and supplier of in-vitro diagnostic test kits with an extensive product panel of non-radioactive (ELISA) and radioactive (RIA) test systems as well as LC-MS/MS reagents. To ensure the quality of our products, services, and support, Demeditec is certified according to EN ISO 9001 and EN ISO 13485. The partners of Demeditec are located worldwide including private laboratories, hospitals, universities as well as research institutions and pharmaceutical companies.